skip to Main Content

Cro services in

Lung (IPF)

Accelerate your drug development by exploring clinical pulmonary function endpoints and histopathological readouts in our BLEO-IPF and HFD-BLEO-IPF mouse models. We apply clinically relevant endpoints to ensure model translatability and the understanding of drug mode-of-action.

Why Gubra?
  • In-depth validated mouse models of IPF
  • Spirometry-confirmed lung dysfunction
  • Plethysmography-validated disease stratification at baseline
  • Automated AI-based histopathological scoring
  • Profile compounds using clinical trial endpoints
  • Tailored study design and rapid initiation
Lung_cro_ipf

Consult with Michael Feigh

Vice President, Scientific Sales

Reach out to our experts to learn how we can move your IPF drug pipeline forward

Advance your study in
spirometry-confirmed IPF models


We offer bleomycin-induced IPF mouse models with hallmarks of lung dysfunction confirmed by spirometry and plethysmography. Our advanced study design allows for therapeutic intervention assessing anti-fibrotic efficacy.

Main Offerings

Lung function testing
Spirometry & Plethysmography

Biochemical assessment
Plasma, Lung & BALF

Histopathological
Ashcroft scoring

Quantitative histology
Inflammation & fibrosis

Lung transcriptomic profile

advanced bleomycin models

Idiopathic Pulmonary Fibrosis (IPF) Models

Related pages

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top